@article {Rapoport1137, author = {B. L. Rapoport and D. A. Vorobiof and C. Slabber and A. S. Alberts and H. S. Hlophe and C. Mohammed}, title = {Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer}, volume = {19}, number = {6}, pages = {1137--1141}, year = {2009}, doi = {10.1111/IGC.0b013e3181a8b938}, publisher = {BMJ Specialist Journals}, abstract = {Objective: This phase II study assessed the activity and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin in relapsed ovarian cancer (ROC).Method: Forty women with platinum-sensitive and partially platinum-sensitive ROC were treated with PLD 50 mg/m2 plus carboplatin area under the curve 5 every 28 days in this South African multicenter study. All patients who completed 3 cycles of chemotherapy were evaluated for response. Primary outcome was response in the intent-to-treat population.Results: Complete response was 35\%, and partial response was 32.5\% (overall response, 67.5\%). Median time-to-progression was 11.9 months, and median survival was 30.0 months. Overall response was higher in platinum-sensitive (81\%) versus partially platinum-sensitive patients (53\%), as were median duration of response, median time-to-progression, and median survival. Treatment was well tolerated, with no grade 4 nonhematologic toxicities. Grade 3/4 hematologic toxicities included leukopenia (58\%), neutropenia (55\%), and thrombocytopenia (43\%).Conclusion: Pegylated liposomal doxorubicin plus carboplatin is well tolerated and active in the treatment of platinum-sensitive and partially platinum-sensitive ROC.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/19/6/1137}, eprint = {https://ijgc.bmj.com/content/19/6/1137.full.pdf}, journal = {International Journal of Gynecologic Cancer} }